Envafolimab combined with chemotherapy in the treatment of combined small cell lung cancer: A case report

Abstract

BACKGROUND Combined small cell lung cancer (C-SCLC) is a special subtype of small cell lung cancer that is relatively rare, aggressive, and prone to early metastasis and has a poor prognosis. Currently, there are limited studies on C-SCLC, and there is no uniform standard treatment, especially for extensive C-SCLC, which still faces great challenges. In recent years, the development and progress of immunotherapy have provided more possibilities for the treatment of C-SCLC. We used immunotherapy combined with first-line chemotherapy to treat extensive-stage C-SCLC to explore its antitumor activity and safety. CASE SUMMARY We report a case of C-SCLC that presented early with adrenal, rib, and mediastinal lymph node metastases. The patient received carboplatin and etoposide with concurrent initiation of envafolimab. After 6 cycles of chemotherapy, the lung lesion was significantly reduced, and the comprehensive efficacy evaluation showed a partial response. No serious drug-related adverse events occurred during the treatment, and the drug regimen was well tolerated. CONCLUSION Envafolimab combined with carboplatin and etoposide in the treatment of extensive-stage C-SCLC has preliminary antitumor activity and good safety and tolerability.

Efficacy and safety of Xiao-ai-ping injection add-on therapy to chemotherapy in patients with non-small cell lung cancer: A systematic review and meta-analysis

“…The dose of XAPI was 4~80 mL/day, the course of treatment was 1 to 4 cycles. In these studies, the most common schemes are gemcitabine + cisplatin, [18–22,29,31–37,39] taxol + cisplatin [26–28,30,36,40] and navelbine + cisplatin [23,33–36] schemes. According to the pathological TNM staging of NSCLC, all the patients included in the study were III to IV stage diseases.…”

“…In the included studies, 27 trials [13–28,30–40] reported the ORR of the 2 groups, a total of 1947 patients, including the treatment group (n = 973) and the control group (n = 974). There was no statistical difference between the studies ( P = .97 and I 2 = 0.0%), so the fixed effect model was used.…”

“…Included 28 studies published between 2009 and 2020. [13–40] All these studies were carried out in China. Overall, 1947 patients with NSCLC (974 receiving XAPI combined chemotherapy and 973 receiving chemotherapy alone) were identified and included in this meta-analysis.…”

“…A total of 6 articles [ 17 , 19 , 23 , 29 , 36 , 39 ] reported immune function, among which the immune indexes involved were CD3+, CD4+, CD8 + and CD4+/CD8+. Three of them [ 19 , 23 , 36 ] reported CD3+.…”

“…A total of 6 articles [ 17 , 19 , 23 , 29 , 36 , 39 ] reported immune function, among which the immune indexes involved were CD3+, CD4+, CD8 + and CD4+/CD8+. Three of them [ 19 , 23 , 36 ] reported CD3+. After meta analysis, the results were statistically homogeneous (χ 2 = 3.22, P = .20, I 2 = 38%), analyzed by fixed effect model, MD = 11.84, 95% CI (11.07, 12.60), P < .00001.…”